DBV.PA DBV Technologies EURONEXT earnings intraday: Q4 due 23 Mar 2026, watch Viaskin

DBV.PA stock trades at €3.30 as investors prepare for DBV Technologies S.A.’s Q4 earnings due 23 Mar 2026 at 16:30 UTC. Expect the report to focus on Viaskin clinical progress and cash runway. Today’s intraday price range is €3.26–€3.35 on volume 174,336, below the 50-day average of €3.68. This earnings spotlight outlines what analysts watch, key ratios, and short-term trade triggers for DBV.PA stock.

Earnings preview: DBV.PA stock — timing and headline catalysts

DBV.PA stock will report on 23 Mar 2026 at 16:30 UTC; management commentary on Viaskin Peanut and Viaskin Milk is the main near-term catalyst. One paragraph: Investors will look for updates on regulatory paths, enrollment timelines and any guidance on cash burn. One paragraph: A surprise on clinical timing or partner updates with Nestlè Health Science could swing shares given the small market cap of €576.62M.

Financial snapshot: DBV.PA stock ratios and recent trends

DBV Technologies S.A. shows negative profitability with EPS -0.91 and PE -3.75. One paragraph: Revenue per share is €0.01, operating cash flow per share is -€1.02, and cash per share is €0.73, leaving a current ratio of 1.80. One paragraph: Year high is €4.50, year low €0.68, and YTD change is 4.28%. These figures underline a clinical-stage biotech profile: high R&D intensity (R&D/Revenue 79.82%) and limited operating revenues.

Market reaction and technicals for DBV.PA stock

DBV.PA stock is trading below its 50-day average €3.68 but above its 200-day average €2.54, signalling mixed momentum. One paragraph: Intraday move is down -3.09% with a day low €3.26 and day high €3.35 on volume 174,336 (avg 1,433,796). One paragraph: Technical indicators show RSI 41.21 and MACD histogram -0.05, consistent with near-term weakness but not deeply oversold; Bollinger middle band sits at €3.68 so watch a break of €3.25 for added selling pressure.

Risks and opportunities in DBV.PA stock outlook

DBV.PA stock’s upside depends on clinical and regulatory progress for Viaskin programs; positive data or accelerated approvals would be material. One paragraph: Key risks include continued cash burn, trial delays, and a thin trading float that amplifies moves. One paragraph: Opportunities include partnerships, incremental data readouts for Viaskin Milk, and broader biotech sector strength; healthcare sector peers trade at an average PE 29.10, highlighting a valuation gap for DBV.PA stock.

Meyka AI rating and DBV.PA stock forecast

Meyka AI rates DBV.PA with a score out of 100: Meyka AI rates DBV.PA with a score of 67.10 / 100 and assigns a B — HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. One paragraph: Meyka AI’s forecast model projects a 12-month price of €4.16, a quarterly target of €4.91, and a monthly target of €4.31. Versus the current price €3.295, the 12-month forecast implies an upside of 26.29%. Forecasts are model-based projections and not guarantees.

Trading checklist and price targets for DBV.PA stock

One paragraph: Short-term support sits near €3.00 and stronger support at the 200-day average €2.54. One paragraph: Reasonable intraday price targets ahead of earnings: conservative €4.16 (12-month), base €4.90 (quarterly upside if catalysts land), and a downside scenario €2.50 if trials or cash guidance disappoint. One paragraph: Use size limits given average volume and consider a news-driven stop below €3.00.

Final Thoughts

DBV.PA stock is an intraday earnings play with clinical catalysts concentrated in Viaskin programs. One paragraph: At €3.295 the shares reflect clinical-stage risk: negative EPS -0.91, limited revenues, and high R&D spending. One paragraph: Management commentary on cash runway and trial timelines will move the stock; today’s intraday range €3.26–€3.35 shows current sensitivity. One paragraph: Meyka AI’s forecast model projects a 12‑month price of €4.16, implying a 26.29% upside versus the current price €3.295. These model-based figures are projections and not guarantees. One paragraph: For traders, watch guidance and any partner updates; for longer-term investors, weigh clinical readouts, cash burn, and the healthcare sector backdrop before adjusting exposure. Meyka AI provides this analysis as an AI-powered market analysis platform to support research, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.